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ABSTRACT
Haemostatic abnormalities frequently occur during sepsis and are most often attributed to disseminated intravascular coagulation (DIC). 
We report the case of a patient with severe coagulopathy acquired during fulminant S. aureus sepsis. DIC was not present. This coagulopathy 
was most likely caused by S. aureus exotoxins forming inhibitory complexes with coagulation factor Xa.
LEARNING POINTS
•	 To	our	knowledge,	this	is	the	first	report	describing	inhibition	of	coagulation	by	Staphylococcus aureus in vivo and so will hopefully broaden 
our knowledge of S. aureus sepsis, S. aureus exotoxins and coagulation disorders during sepsis.
• While disseminated intravascular coagulation (DIC) is the most frequent severe coagulopathy diagnosed during sepsis, inhibition of 
coagulation by SSL10 may be an underdiagnosed cause during S. aureus sepsis.
• As DIC and inhibition of coagulation by SSL10 should be treated differently, we emphasize the importance of considering inhibition of 
blood coagulation by S. aureus when an acquired coagulopathy is found during severe sepsis.
KEYWORDS
Staphylococcus aureus, coagulopathy, staphylococcal superantigen-like protein, coagulation factor Xa, disseminated intravascular coagulation
BACKGROUND
Staphylococcus aureus sepsis is a common cause of both hospital-acquired and community-acquired bacteraemia, with overall mortality rates 
of 20–40%[1, 2]. This sepsis frequently results in metastatic infections, with a negative impact on patient outcome. S. aureus infections should 
be	treated	with	antibiotics,	for	example	flucloxacillin	(floxacillin).	
Haemostatic abnormalities are often present during sepsis, ranging from subclinical activation of blood coagulation, to acute disseminated 
intravascular	coagulation	(DIC).	DIC	is	characterized	by	massive	thrombin	and	fibrin	formation,	resulting	in	widespread	thrombosis.	The	
administration of platelets and coagulation proteins during fulminant DIC may cause simultaneous bleeding[1]. 
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A previous in vitro study showed that haemostatic abnormalities during S. aureus sepsis can also result from inhibition of blood coagulation 
by S. aureus itself[3]. To our knowledge, this inhibition has not yet been demonstrated in vivo.
In this case report, we present a patient with severe coagulopathy acquired during fulminant S. aureus sepsis, most likely caused by inhibition 
of coagulation factor X by S. aureus exoproteins.
CASE PRESENTATION
A 60-year-old man with a history of diabetes mellitus type 2, was admitted to our hospital with symptoms of coughing and fever. An x-ray of 
the	thorax	showed	an	infiltrate	of	the	left	lung.	Treatment	with	amoxicillin	and	ciprofloxacin	was	initiated	for	severe	pneumonia.	Two	days	
after admission, blood cultures showed S. aureus.	Medication	was	switched	to	flucloxacillin.	No	metastatic	infections	were	found	on	PET-CT	
imaging	combined	with	transoesophageal	echocardiography.	The	patient	developed	atrial	fibrillation,	for	which	rivaroxaban	(20	mg	once	
daily) was initiated. However, 6 days after initiation, the rivaroxaban was stopped because of a decline in renal function.
Five	days	after	 the	cessation	of	 rivaroxaban	and	15	days	after	 the	first	blood	cultures	 showing	S.	aureus,	blood	coagulation	 tests	were	
performed, preceding a kidney biopsy. These coagulation tests revealed a partial thromboplastin time (PT) of over 90 sec and an activated 
partial thromboplastin time (aPTT) of 83 sec. Apart from an episode of haematuria, our patient did not have any bleeding complications. PT 
and aPTT values from the day of hospital admission (day 0) to 3 months afterwards, as well as other laboratory values, are shown in Table 1. 
Further investigation of the coagulation revealed no signs of DIC. Mixing studies showed complete normalization of clotting times, thus 
excluding the presence of a clotting factor inhibitor. Coagulation factor activity tests revealed normal activity of clotting factors V, VII and 
VIII,	and	a	deficiency	of	clotting	factor	X	(Table 1). Lastly, the serum drug concentration of rivaroxaban on day 16 was 2 µg/l, which is far 
below the therapeutic range[4].  As shown in Table 1, both the PT and aPTT normalized spontaneously 3 weeks after hospital admission.
Table 1. Laboratory values after admission to hospital 
*During treatment with rivaroxaban (treatment with rivaroxaban 20 mg once daily was given between day 4 and day 10 after admission to hospital). 
†During treatment with acenocoumarol. 
§Day of hospital discharge. 
Normal values: haemoglobin 8.4–10.8 mmol/l; platelets 150–400 ×109/l; aPTT 24–34 sec; PT 12–15 sec; creatinine 60–110 µmol/l; eGFR >90 ml/min/1.73m2 (calculated 
with the CKD-EPI equation); fibrinogen 2–4 g/l; factor V activity 70–150%; factor VII activity 60–140%; factor VIII activity 50–200%; factor X activity 60–140%. 
Laboratory values Number of days after admission to hospital
0 8* 15 16 18 22 24†§ 94†
Haemoglobin, mmol/l 9.4 8.6 7.8 7.5 7.7 7.0 6.4 7.0
Platelets, ×109/l 165 344 328 300 320 223 186 219
aPTT, sec 39 41 83 87 63 43 53 42
PT, sec 18 20 >90 >90 34 18 23 25
Creatinine, µmol/l 90 346 692 702 674 450 294 111
eGFR, ml/min/1.73m2 79 16 7 7 7 11 19 58
Fibrinogen, g/l 5
Factor V activity, % 129
Factor VII activity, % >200
Factor VIII activity, % >200
Factor X activity, % 12
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DISCUSSION
We have described the case of a patient with severe coagulopathy acquired during fulminant S. aureus sepsis.	A	solitary	deficiency	of	factor	
X was found and other causes of combined PT and aPTT prolongation were excluded. The coagulopathy was most likely caused by inhibition 
of coagulation factor X by the S. aureus exotoxins staphylococcal superantigen-like proteins (SSLs). The bleeding disorder disappeared 
simultaneously with resolution of the sepsis. 
Fig. 1	shows	a	simplified	version	of	the	coagulation	cascade.	As	a	solitary	deficiency	of	factor	X	was	found,	the	acquired	coagulopathy	was	
less	 likely	caused	by	 liver	disease,	vitamin	K	deficiency,	DIC,	warfarin	 intoxication	or	rodenticide	poisoning.	The	rivaroxaban	blood	drug	
concentration was subtherapeutic, excluding anticoagulant overdosage. A factor X inhibitor was excluded and there were no signs of 
rapid-onset amyloid light-chain amyloidosis, or multiple myeloma. A previous literature study showed S. aureus is able to inhibit host blood 
coagulation by inhibiting clotting factor X[3].	As	all	other	possible	causes	of	an	acquired	factor	X	deficiency	were	excluded,	we	concluded	that	
inhibition of clotting factor X by S. aureus was the most likely cause of the acquired coagulopathy in our patient. 
Figure 1. The coagulation cascade
Superantigens (SAgs) and SSLs are exoproteins produced by S. aureus. SAgs exhibit superantigenic activity, which means they act by causing 
activation of T cells. They are important in a variety of diseases, including toxic shock syndrome (TSS), Kawasaki disease, staphylococcal 
pneumoniae and staphylococcal purpura fulminans[2]. SSLs do not exhibit superantigenic activity. Earlier studies demonstrated that SSLs are 
able to disturb host immune functions and inhibit blood coagulation in a T-cell-independent way[3].
Several SSLs disturb host immune function. For example, SSL3 binds to Toll-like receptor 2 and inhibits cytokine production by macrophage[5,6], 
while SSL10 inhibits the classical complement activation pathway, the migration of T cells, the interaction between complement C1q and 
IgG, and the Fc-receptor-mediated phagocytosis of neutrophils[7–9].
Previous in vitro studies showed that SSL10 is also able to inhibit blood coagulation[3].	This	exoprotein	binds	specifically	to	coagulation	factor	
Xa and prothrombin, two major factors involved in the blood coagulation cascade (Fig. 1). Due to this binding, the generation of thrombin is 
reduced, blood coagulation is inhibited and clotting times are prolonged in a dose-dependent way.
Since extreme prolongation of clotting times was found in our patient, we believe he was infected with a strain of S. aureus which produced 
more	SSL10	than	average.	However,	we	could	not	find	a	circulating	inhibitor	of	factor	X,	since	mixing	studies	revealed	complete	normalisation	
of clotting times. 
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We speculate that all of the SSL10 was already bound to factor X when coagulation tests were carried out. In an attempt to detect the 
presence of SSL10 in the in vitro culture supernatant of this strain, we performed SDS-PAGE and Western blot analysis with an SSL10-
specific	antiserum.	These	tests	did	not	detect	the	presence	of	SSL10	in	the	bacterial	culture	supernatant	under	these	conditions.	It	is	known	
that	the	detection	of	many	SSLs	in	the	culture	supernatants	of	various	strains	and	under	different	conditions	in	vitro	is	difficult,	most	likely	
caused by low levels of secretion in vitro[10]. This may be the reason why we were unable to detect the presence of SSL10 in the bacterial 
supernatant,	and	does	not	exclude	the	presence	of	significant	in	vivo	levels.
Inhibition of coagulation factor X by S. aureus SSL10 is the most likely cause of the acquired coagulopathy in our patient. To our knowledge, 
no earlier reports have described this coagulopathy in vivo. While DIC is the most frequently diagnosed severe coagulopathy during sepsis, 
inhibition of coagulation by SSL10 may be an underdiagnosed cause during S. aureus sepsis. 
A	solitary	factor	X	deficiency	with	bleeding	complications	is	best	treated	with	coagulation	factor	concentrate,	while	treatment	of	DIC	should	
primarily focus on addressing the underlying cause. Therefore, we emphasize the importance of considering inhibition of blood coagulation 
by S. aureus when an acquired coagulopathy is found during severe sepsis.
CONCLUSION
We have described a patient with severe coagulopathy acquired during fulminant S. aureus sepsis, most likely caused by S. aureus exotoxins 
forming	 inhibitory	complexes	with	coagulation	 factor	Xa.	To	our	knowledge,	 this	 is	 the	first	demonstration	of	 this	 inhibition	 in	humans.	
However, this may be a more common and underdiagnosed cause of acquired coagulopathy during S. aureus sepsis. As treatment of a solitary 
factor	X	deficiency	is	different	from	the	treatment	of	DIC,	we	emphasize	the	importance	of	considering	inhibition	of	blood	coagulation	by	S. 
aureus when acquired coagulopathy is found during severe sepsis.
